Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism

Kidney International

Volumn 88, Issue 2, 2015, Pages 350-359

  Komaba, Hirotaka ^a   Taniguchi, Masatomo ^b   Wada, Atsushi ^b   Iseki, Kunitoshi ^b   Tsubakihara, Yoshiharu ^b   Fukagawa, Masafumi ^a  

^a TOKAI UNIVERSITY   (Japan)

^b Scientific Academic Committee of the Japanese Society for Dialysis Therapy   (Japan)

Author keywords

hemodialysis; hyperparathyroidism; parathyroid hormone; survival

Indexed keywords

PARATHYROID HORMONE; CALCIUM; PHOSPHORUS;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT HISTORY OF PARATHYROIDECTOMY; PRIORITY JOURNAL; PROPENSITY SCORE; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS; SURVIVAL RATE; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; EPIDEMIOLOGY; HYPERPARATHYROIDISM, SECONDARY; JAPAN; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PARATHYROIDECTOMY; REGISTER; RENAL REPLACEMENT THERAPY;

AGED; CALCIUM; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROIDECTOMY; PHOSPHORUS; PROPENSITY SCORE; REGISTRIES; RENAL DIALYSIS; SURVIVAL RATE;

EID: 84938550943     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.72     Document Type: Article

References (40)

1. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277
2. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
3. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
4. Taniguchi M, Fukagawa M, Fujii N et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 2013; 17: 221-228
5. Punch JD, Thompson NW, Merion RM. Subtotal parathyroidectomy in dialysis-dependent and post-renal transplant patients. A 25-year singlecenter experience. Arch Surg 1995; 130: 538-543
6. Stracke S, Jehle PM, Sturm D et al. Clinical course after total parathyroidectomy without autotransplantation in patients with endstage renal failure. Am J Kidney Dis 1999; 33: 304-311
7. Chou FF, Ho JC, Huang SC et al. A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll Surg 2000; 190: 65-70
8. Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1442
9. Kifor O, Moore FD Jr, Wang P et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 1598-1606
10. Lafrance JP, Cardinal H, Leblanc M et al. Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC Nephrol 2013; 14: 100
11. The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494
12. Gagné ER, Ureña P, Leite-Silva S et al. Short- and long-Term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992; 3: 1008-1017
13. Gasparri G, Camandona M, Abbona GC et al. Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Ann Sur 2001; 233: 65-69
14. Tominaga Y, Uchida K, Haba T et al. More than 1, 000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis 2001; 38: S168-S171
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76: S1-S130
16. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201
17. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008; 12: 514-525
18. Kestenbaum B, Andress DL, Schwartz SM et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010-2016
19. Trombetti A, Stoermann C, Robert JH et al. Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism. World J Surg 2007; 31: 1014-1021
20. Costa-Hong V, Jorgetti V, Gowdak LH et al. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery 2007; 142: 699-703
21. Iwamoto N, Sato N, Nishida M et al. Total parathyroidectomy improves survival of hemodialysis patients with secondary hyperparathyroidism. J Nephrol 2012; 25: 755-763
22. Lin HC, Chen CL, Lin HS et al. Parathyroidectomy improves cardiovascular outcome in nondiabetic dialysis patients with secondary hyperparathyroidism. Clin Endocrinol (Oxf) 2014; 80: 508-515
23. Amann K, Ritz E, Wiest G et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994; 4: 1814-1819
24. Rashid G, Bernheim J, Green J et al. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 2007; 292: F1215-F1218
25. Hamano T, Matsui I, Mikami S et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 2010; 21: 1998-2007
26. Drüeke T, Fauchet M, Fleury J et al. Effect of parathyroidectomy on left-ventricular function in haemodialysis patients. Lancet 1980; 1: 112-114
27. Nagashima M, Hashimoto K, Shinsato T et al. Marked improvement of left ventricular function after parathyroidectomy in a hemodialysis patient with secondary hyperparathyroidism and left ventricular dysfunction. Circ J 2003; 67: 269-272
28. Bleyer AJ, Burkart J, Piazza M et al. Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 2005; 46: 464-469
29. Rudser KD, De Boer IH, Dooley A et al. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18: 2401-2407
30. Trunzo JA, McHenry CR, Schulak JA et al. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery 2008; 144: 915-919
31. Goldsmith DJ, Covic AA, Venning MC et al. Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 1996; 27: 819-825
32. Zhang J, Yu X, Sun B et al. Parathyroidectomy and heart rate variability in patients with stage 5 CKD. Clin J Am Soc Nephrol 2013; 8: 1378-1387
33. Yasunaga C, Nakamoto M, Matsuo K et al. Effects of a parathyroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism. Am J Surg 1999; 178: 332-336
34. Chou FF, Lee CH, Lee CT. Muscle force and bone mineral density after parathyroidectomy and subcutaneous autotransplantation for secondary hyperparathyroidism. World J Surg 1999; 23: 452-457
35. Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44: 481-487
36. Takahashi H, Komaba H, Takahashi Y et al. Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab 2014; 99: E652-E658
37. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
38. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
39. Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf 2008; 17: 1202-1217
40. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457